Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Nuedexta Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Nuedexta Coverage for Pseudobulbar Affect

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs UnitedHealthcare prior authorization and medical-necessity coverage for Nuedexta (dextromethorphan/quinidine) for members with pseudobulbar affect. It applies to initial authorization and reauthorization requests in the commercial pharmacy benefit.

    Policy Summary
    PayerUnitedHealthcare
    PolicyNuedexta Coverage for Pseudobulbar Affect
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument pseudobulbar affect, at least one qualifying neurologic condition, absence of cardiac rhythm disorders, and neurologist involvement for initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    6Qualifying neurologic conditions
    1Covered medication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy

    Nuedexta will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of pseudobulbar affect
    • ONE of the following

      • Amyotrophic lateral sclerosis (ALS)
      • Alzheimer's disease
      • Multiple sclerosis (MS)
      • Parkinson's disease
      • Stroke
      • Traumatic brain injury
    • Documented absence of cardiac rhythm disorders
    • Prescribed by or in consultation with a neurologist

    Continuation Therapy

    Nuedexta will be approved based on the following criterion:

    Documentation of positive clinical response to therapy

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Nuedexta approval. UnitedHealthcare will conduct a medical-necessity review before authorization is issued.

    Prior Authorization

    Reauthorization Requirements

    Reauthorization requires documentation of a positive clinical response to Nuedexta. When approved, reauthorization will be issued for 12 months.

    Documentation Required

    Initial Authorization Documentation

    Submit documentation supporting each initial-authorization requirement for Nuedexta.

    • Diagnosis of pseudobulbar affect.
    • One qualifying neurologic condition: amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, multiple sclerosis (MS), Parkinson’s disease, stroke, or traumatic brain injury.
    • Documented absence of cardiac rhythm disorders.
    • Prescription by or consultation with a neurologist.

    Unsupported block type: documentation

    Denial Risk

    Initial Authorization Criteria Not Met

    Initial authorization may be denied when the required clinical criteria are not satisfied.

    • Pseudobulbar affect is not documented.
    • No qualifying neurologic condition is documented.
    • A cardiac rhythm disorder is present or the required absence of such disorders is not documented.
    • The prescription is not from or in consultation with a neurologist.
    Denial Risk

    Positive Clinical Response Not Documented

    Reauthorization may be denied when documentation does not establish a positive clinical response to Nuedexta.

    Nuedexta and Pseudobulbar Affect

    Nuedexta (dextromethorphan/quinidine) is a combination product containing dextromethorphan hydrobromide and quinidine sulfate. It is indicated for the treatment of pseudobulbar affect (PBA), a condition that may occur secondary to various neurologic conditions and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. These episodes are typically out of proportion to, or inappropriate for, the underlying emotional state. PBA is distinct from other forms of emotional lability associated with neurologic disease or injury.

    Key Definition

    Pseudobulbar Affect
    DefinitionPseudobulbar affect is a specific condition characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.
    Emotional relationshipEpisodes typically occur out of proportion or are inappropriate to the underlying emotional state.
    Clinical distinctionPseudobulbar affect is distinct from other types of emotional lability that may occur in patients with neurologic disease or injury.

    Nuedexta Initial Authorization

    Nuedexta Initial Authorization

    Nuedexta will be approved based on ALL of the following criteria.

    Initial authorization

    • Diagnosis of pseudobulbar affect.
    • ONE qualifying neurologic condition

      • Amyotrophic lateral sclerosis (ALS).
      • Alzheimer's disease.
      • Multiple sclerosis (MS).
      • Parkinson's disease.
      • Stroke.
      • Traumatic brain injury.
    • Cardiac safety: Documented absence of cardiac rhythm disorders.
    • Neurologist involvement: Prescribed by or in consultation with a neurologist.

    Nuedexta Reauthorization

    Nuedexta Reauthorization

    Reauthorization requires documentation of a positive clinical response to therapy.

    Positive clinical response: Documentation of positive clinical response to therapy.
    Policy Summary
    PayerUnitedHealthcare
    PolicyNuedexta Coverage for Pseudobulbar Affect
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionDocument pseudobulbar affect, at least one qualifying neurologic condition, absence of cardiac rhythm disorders, and neurologist involvement for initial authorization.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsNuedexta and Pseudobulbar AffectKey DefinitionNuedexta Initial AuthorizationNuedexta Reauthorization